Well-poised to improve earnings outlook

Company
12 Dec 2023
5 Min read 
  • Torrent Pharma is well-positioned to improve earnings with efforts to scale up and improve profitability.
  •  Focus on derma therapy and prescription-led portfolio to drive growth.
  •  Strengthened MR force and product launches in the Brazilian market.
  •  Clearance of Dahej site by USFDA expected to boost US generics business.
  •  Strong sales, EBITDA, and PAT growth expected in the next few years.
  •  Valuation suggests limited upside, maintaining a neutral stance.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities